Paul Navarre is responsible for all Ferring US activities including commercial operations, clinical development and manufacturing.
Paul has more than 25 years of experience in the pharmaceuticals and consumer goods industries. Before joining Ferring in 2017, he was President of Allergan International where he managed a $3 billion specialty care business covering dermatology, ophthalmology, urology and neurosciences. Paul began his career in consumer goods at Procter & Gamble before moving to the company’s pharmaceutical division. During his 15 years at P&G, he held a positions of increasing responsibility in France, the USA, Switzerland, Italy and the UK.
Paul holds a Master of Business Administration degree from the ISC Paris Business School in Paris, France.
Stacey Antar is responsible for all Ferring US legal affairs.
Stacey has more than 25 years of experience in life sciences law. Prior to joining Ferring in 2014, Stacey was counsel for Johnson & Johnson for 18 years where she provided legal counsel in both the pharmaceutical and medical device sectors. Stacey served as Vice President, Law and served as a member of the global management board for Ortho-Clinical Diagnostics. Throughout her time at Johnson & Johnson, she served as a member of executive leadership teams for several operating companies and the law department’s Diversity and Inclusion committee. Stacey began her legal career as a patent attorney at Finnegan, Henderson, Farabow, Garrett & Dunner in Washington, D.C.
Stacey received her J.D. from Columbus School of Law, Catholic University of America in Washington, D.C. She earned her B.S. summa cum laude from the University of Massachusetts, Amherst. In 2016 Stacey was a recipient of the Women of Power & Influence Award by National Organization for Women NY.
Joan-Carles Arce is responsible for Ferring US drug development activities, regulatory affairs, pharmacovigilance and medical affairs.
Joan-Carles has more than 25 years of experience in the pharmaceutical industry. Prior to joining Ferring US in 2016, he was Vice President of Science & Medicine for Reproductive Health and Vice President of Global Clinical Development Support at the Ferring International PharmaScience Center in Denmark. Before joining Ferring in 2002, he worked for Novo Nordisk in Denmark, and earlier for Merck KGaA-Lipha in France. Joan-Carles has authored more than 100 publications and has presented at numerous scientific meetings and industry conferences.
Joan-Carles received his M.D. from the Autonomous University of Barcelona Medical School in Spain, and a Ph.D from the Free University Faculty of Medicine and Pharmacy in Brussels, Belgium. He conducted a postdoctoral fellowship at the University of Connecticut Health Center.
Bipin Dalmia is responsible for all Ferring US business development activities and is a key member of the Ferring Global Business Development group.
Bipin has over 25 years of experience in pharmaceuticals and biotechnology industries, starting as a research scientist and transitioning early in his career to licensing and business development. Before joining Ferring in 2012, he held roles of rapidly increasing responsibilities at Biolex Therapeutics, Syngenta and Novartis. During his 20 year business development career, he has led to conclusion over 50 transactions, both on the buy and sell sides, in biotech, specialty pharma and big pharma across several therapeutic areas and development stages.
Bipin holds a MBA degree from Drake University in Des Moines, Iowa, and a Ph.D. in Chemical Engineering from Iowa State University in Ames, Iowa.
Ayana Champagne is responsible for Ferring US human resources.
Ayana has nearly 20 years of global human resources experience in private and public market-leading, multi-national organizations. Before joining Ferring in 2017, she was Senior HR Director at United Technologies, a $65 billion fortune 50 company, where she supported the Global Aftermarket Operations organization responsible for 5,000+ employees and a $3.6 billion P&L. Prior to United Technologies, Ayana worked for Eaton Corporation ($16 billion revenue), a diversified industrial manufacturer, where she held various positions of increasing HR responsibility.
Ayana holds a Bachelor of Science degree in Finance from Bradley University, and dual master’s degrees in technology and operations management, and human resources management from Aurora University. In addition, Ayana holds several HR related certificates.
Einat Frydman is responsible for Ferring US product supply operations.
Einat is an executive with 25 years of pharmaceutical, medical device, biotechnology and life science operations experience, including early-stage, pre-commercial start-up, and commercial manufacturing. Her management experience includes API & Sterile FP manufacturing, materials, engineering, facilities, EH&S, process development, commercial development, validation, distribution and cost modeling. She also has extensive experience in quality manufacturing and quality operations. Prior to assuming her current role, Einat was General Manager of Bio-Technology General (Israel) Ltd., a Ferring Group company and manufacturer of EUFLEXXA® (1% sodium hyaluronate). Before joining Ferring, she spent 18 years with Teva Pharmaceuticals in a variety of positions of increasing responsibility, such as Head of Regulatory Compliance and Head of Quality Assurance, and finally as Executive Director of the sterile manufacturing plant in Israel producing 40 M sterile units for 40 destinations around the world.
Einat holds a Bachelor of Science in Chemical Engineering from Technion – Israel Institute of Technology.
Mike Magee is responsible for quality assurance within Ferring US commercial operations, development and manufacturing.
Mike joined Ferring in 2015 from Discovery Laboratories, Inc. where he was Vice President, Technical Operations responsible for quality and manufacturing. Prior to that he spent 23 years with Johnson & Johnson in roles of increasing responsibility as he established his expertise in quality operations, manufacturing, and technical services for pharmaceutical and biopharmaceutical drug products.
Mike holds a Bachelor of Science degree in chemistry from Moravian College and a Bachelor of Science degree in pharmacy from Philadelphia College of Pharmacy and Science. He is a registered pharmacist in New Jersey.
Sophie Opdyke is responsible for building the U.S. Oncology division, leading its day-to-day operations, and shaping its long-term strategic business plan. This includes leading the potential commercial launch of an investigational gene therapy for high-grade, non-muscle invasive bladder cancer patients, who are unresponsive to BCG therapy.
Sophie joined Ferring in January, 2019. She has more than 20 years of experience in the pharmaceutical industry. Most recently at Pfizer, she led the development and execution of Pfizer’s strategy in Immuno-Oncology. Specifically, she oversaw all associated commercial activities from pre-clinical through launch for the company’s portfolio, including check point inhibitors, novel Immuno-Oncology targets and innovative technologies such as allogenic CAR-T and immune therapy-based vaccines. During her tenure, Opdyke was also instrumental in building and leading Pfizer’s Global Biosimilars organization, driving a core component of its biotherapeutics strategy.
Sophie holds a doctorate of Pharmacy and Master of Pharmaceutical Business from Université Paris Descartes and an MBA in finance and international business from Columbia Business School.
Brent Ragans is responsible for Ferring US commercial activities.
Brent has more than 25 years of experience in the pharmaceutical industry. Before joining Ferring in 2012, he built and led several multi-billion dollar brands for Sanofi, where his last position was Senior Vice President of North American Consumer Healthcare Strategy and Corporate Development. Brent began his career at Bock Pharmaceuticals.
Brent holds a Bachelor of Science degree in Legal Communications and Marketing from Florida State University.
Stefan Vaughn is responsible for leadership and oversight of the finance function and related processes for the US organization.
Stefan has nearly 20 years of finance experience in manufacturing, consumer goods, biopharmaceuticals, and consulting. He has held successive leadership roles in US and international commercial finance, including as Asia Pacific CFO for Takeda Pharmaceuticals, a $1 billion business. At Takeda, he supported the business transformation of commercial operations, business development, ERP implementation programs, and global operational efficiency initiatives designed to reduce duplication and complexity.
Prior to Takeda, Stefan worked for Robert Bosch Tool Corporation, CF Industries and McBee Associates in various finance positions.
He holds a Masters of Business Administration from DePaul University and a Bachelor’s of Science in Finance from University of Maryland.
Joe Zimmerman is responsible for all aspects of healthcare compliance for the Ferring US operations.
Joe has more than 20 years of experience in the pharmaceutical industry. He has held senior roles in compliance and ethics, privacy, leadership development training, and sales. Previously, Joe served as Senior Vice President and Chief Compliance Officer for Actavis and Corporate Vice President, Global Chief Compliance Officer for Forest Laboratories both now known as Allergan. Joe was directly involved as both Compliance Officer and Executive Team Member in numerous mergers and acquisitions while at Actavis and Forest. He has launched and provided compliance support to multi-billion dollar brands.
He holds a degree in biology from Bradley University and has received additional certifications in compliance, ethics, fraud & abuse, and investigations.